RecruitingNot Applicable

A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer

India20 participantsStarted 2023-02-01

Plain-language summary

The aim of the study is to test the feasibility \& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 18 or above and less than 75 years.
✓. Histologically proven non-small cell lung cancer.
✓. Stage T1-4, N1-3, M0 with maximum tumor size less than 6 cms and ≤ 3 stations of largest lymph node size less than 4 cms.
✓. ECOG status 0-1.
✓. Available to attend long term follow- up.
✓. Written informed consent for treatment.

Exclusion criteria

✕. Metastatic disease.
✕. Tumor size \> 6cm.
✕. Involved Lymph node size greater than 4 cms \& more than 3 station of lymph nodes involved.
✕. Patients with superior vena cava obstruction.
✕. Tumor invading/encasing the proximal bronchial tree/, esophagus, pericardium.
✕. Previous radiotherapy to thorax.
✕. Small cell histology.
✕. Age\< 18 or \> 75 years.

What they're measuring

Loco-regional control rate

Timeframe: 2 years

Trial details

NCT IDNCT07565987

SponsorAll India Institute of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-30

Contact for this trial

Aman Sharma, MD

+91117018529339 amans757@gmail.com

View on ClinicalTrials.gov More Non Small Cell Lung Cancer trials